# UNITEDHEALTHCARE FORMULARY ANALYSIS: 2025 → 2026


Generated: 2025-12-23 20:06:50
Mode: pdf_direct
Source: uhc_2025.pdf (93 pages)
        uhc_2026.pdf (80 pages)

--------------------------------------------------------------------------------

# UnitedHealthcare Formulary Comparison: 2025 vs 2026

## Executive Summary

This analysis identifies significant changes between the 2025 and 2026 UnitedHealthcare Prescription Drug Lists. Key themes include expanded quantity limits on opioids, new specialty drug additions, generic conversions, and tier restructuring across multiple therapeutic classes.

---

## 1. Drug Additions (New in 2026)

### Brand-Name Additions

| Drug Name       | Therapeutic Class         | Tier   | Requirements |
| --------------- | ------------------------- | ------ | ------------ |
| **JOURNAVX**    | Analgesics                | Tier 4 | QL           |
| **KLOXXADO**    | Anti-Addiction (Naloxone) | Tier 1 | QL           |
| **OPVEE**       | Anti-Addiction (Naloxone) | Tier 1 | QL           |
| **AUGTYRO**     | Antineoplastics           | Tier 2 | PA, QL, SP   |
| **SCEMBLIX**    | Antineoplastics           | Tier 2 | PA, QL, SP   |
| **RYDAPT**      | Antineoplastics           | Tier 2 | PA, QL, SP   |
| **ZILBRYSQ**    | Antimyasthenic Agents     | Tier 4 | PA, QL, SP   |
| **CAPLYTA**     | Antidepressants           | Tier 4 | PA, ST, QL   |
| **RALDESY**     | Antidepressants           | Tier 4 | PA           |
| **VRAYLAR**     | Antidepressants           | Tier 4 | QL           |
| **NUZYRA ORAL** | Antibacterials            | Tier 4 | QL           |
| **MOTPOLY XR**  | Anticonvulsants           | Tier 3 | PA           |

### Generic Additions

| Drug Name                           | Therapeutic Class | Tier   | Notes                                |
| ----------------------------------- | ----------------- | ------ | ------------------------------------ |
| **rivaroxaban** (generic Xarelto)   | Anticoagulants    | Tier 2 | QL - Major cost savings opportunity  |
| **oxcarbazepine**                   | Anticonvulsants   | Tier 1 | Previously only brand available      |
| **lacosamide oral**                 | Anticonvulsants   | Tier 2 | Moved from Tier 3                    |
| **perampanel**                      | Anticonvulsants   | Tier 2 | PA - generic for Fycompa             |
| **eslicarbazepine acetate**         | Anticonvulsants   | Tier 3 | PA - generic for Aptiom              |
| **nilotinib hcl**                   | Antineoplastics   | Tier 2 | PA, ST, QL, SP - generic for Tasigna |
| **torpenz**                         | Antineoplastics   | Tier 2 | PA, QL, SP                           |
| **rivastigmine tartrate**           | Antidementia      | Tier 1 | Specific salt form added             |
| **aripiprazole oral**               | Antidepressants   | Tier 2 | Repositioned from antipsychotics     |
| **calcipotriene external ointment** | Antifungals       | Tier 2 | New addition                         |

### New Naloxone Products (Expanded Access)

| Product          | Tier   | Requirements |
| ---------------- | ------ | ------------ |
| ft naloxone hcl  | Tier 1 | QL           |
| gnp naloxone hcl | Tier 1 | QL           |
| KLOXXADO         | Tier 1 | QL           |
| OPVEE            | Tier 1 | QL           |

---

## 2. Drug Removals (Excluded in 2026)

### Removed from Formulary

| Drug Name                          | 2025 Tier | Therapeutic Class | Impact                             |
| ---------------------------------- | --------- | ----------------- | ---------------------------------- |
| **azithromycin oral packet 1gm**   | Tier 1    | Antibacterials    | Members must use alternative forms |
| **rifabutin**                      | Tier 1    | Antibacterials    | Significant for TB/MAC treatment   |
| **clarithromycin er**              | Tier 2    | Antibacterials    | Use immediate-release instead      |
| **clarithromycin oral suspension** | Tier 2    | Antibacterials    | Pediatric impact                   |
| **granisetron hcl oral**           | Tier 2    | Antiemetics       | Use ondansetron alternatives       |
| **dronabinol**                     | Tier 1    | Antiemetics       | MARINOL remains excluded           |
| **almotriptan malate**             | Tier 3    | Antimigraine      | Use other triptans                 |
| **griseofulvin ultramicrosize**    | Tier 1    | Antifungals       | Only microsize remains             |
| **acamprosate calcium**            | Tier 1    | Anti-Addiction    | Alcohol dependence treatment gap   |
| **galantamine hydrobromide er**    | Tier 1    | Antidementia      | Use donepezil or memantine         |
| **felbamate**                      | Tier 1    | Anticonvulsants   | Specialty seizure medication       |
| **vigabatrin oral packet**         | Tier 2    | Anticonvulsants   | PA, QL, SP - infantile spasms      |
| **rufinamide**                     | Tier 3    | Anticonvulsants   | Lennox-Gastaut syndrome            |
| **FINTEPLA**                       | Tier 4    | Anticonvulsants   | Dravet syndrome                    |
| **fondaparinux sodium**            | Tier 2    | Anticoagulants    | Use enoxaparin                     |
| **ELIQUIS DVT/PE STARTER PACK**    | Tier 2    | Anticoagulants    | Use regular ELIQUIS                |
| **XARELTO STARTER PACK**           | Tier 2    | Anticoagulants    | Use regular XARELTO                |
| **protriptyline hcl**              | Tier 1    | Antidepressants   | Tricyclic antidepressant           |
| **tranylcypromine sulfate**        | Tier 1    | Antidepressants   | MAOI - limited alternatives        |
| **olanzapine-fluoxetine hcl**      | Tier 2    | Antidepressants   | SYMBYAX remains Tier 4             |

### Oncology Removals/Changes

| Drug Name         | 2025 Status | 2026 Status | Notes                |
| ----------------- | ----------- | ----------- | -------------------- |
| **BOSULIF**       | Tier 2      | Not listed  | CML treatment        |
| **GAVRETO**       | Tier 2      | Not listed  | RET fusion cancers   |
| **ICLUSIG**       | Tier 2      | Not listed  | CML/ALL treatment    |
| **NERLYNX**       | Tier 2      | Not listed  | HER2+ breast cancer  |
| **NINLARO**       | Tier 2      | Not listed  | Multiple myeloma     |
| **ZELBORAF**      | Tier 2      | Not listed  | Melanoma             |
| **ZEJULA**        | Tier 2      | Not listed  | Ovarian cancer       |
| **VITRAKVI**      | Tier 2      | Not listed  | NTRK fusion cancers  |
| **BRUKINSA**      | Tier 3      | Not listed  | CLL/lymphoma         |
| **INLYTA**        | Tier 3      | Not listed  | Renal cell carcinoma |
| **KOSELUGO**      | Tier 3      | Not listed  | Neurofibromatosis    |
| **LENVIMA**       | Tier 3      | Not listed  | Thyroid/liver cancer |
| **pazopanib hcl** | Tier 3      | Not listed  | Renal cell/sarcoma   |
| **EXKIVITY**      | Tier 4      | Not listed  | NSCLC                |
| **LONSURF**       | Tier 4      | Not listed  | Colorectal cancer    |
| **TABRECTA**      | Tier 4      | Not listed  | MET+ NSCLC           |
| **TAFINLAR**      | Tier 4      | Not listed  | Melanoma/NSCLC       |
| **MEKINIST**      | Tier 4      | Not listed  | Melanoma/NSCLC       |

---

## 3. Tier Changes

### Moved to Lower Tier (Cost Decrease)

| Drug Name                                       | 2025 Tier | 2026 Tier            | Therapeutic Class |
| ----------------------------------------------- | --------- | -------------------- | ----------------- |
| **rivastigmine**                                | Tier 3    | Tier 1 (as tartrate) | Antidementia      |
| **lacosamide oral**                             | Tier 3    | Tier 2               | Anticonvulsants   |
| **etodolac**                                    | Tier 2    | Tier 1               | NSAIDs            |
| **hydrocodone-acetaminophen solution 10-300mg** | Tier 2    | Tier 1               | Analgesics        |
| **terbinafine hcl oral**                        | Tier 2    | Tier 1               | Antifungals       |
| **divalproex sodium delayed release**           | Tier 2    | Tier 1               | Anticonvulsants   |

### Moved to Higher Tier (Cost Increase)

| Drug Name             | 2025 Tier | 2026 Tier         | Therapeutic Class |
| --------------------- | --------- | ----------------- | ----------------- |
| **APTIOM**            | Tier 3    | Tier 4            | Anticonvulsants   |
| **BRIVIACT**          | Tier 3    | Tier 3 (added PA) | Anticonvulsants   |
| **etodolac er**       | Tier 3    | Removed           | NSAIDs            |
| **mefenamic acid**    | Tier 3    | Removed           | NSAIDs            |
| **NICODERM CQ**       | Tier 1-2  | Tier 4            | Smoking Cessation |
| **NICORETTE GUM**     | Tier 2    | Tier 4            | Smoking Cessation |
| **flurbiprofen oral** | Tier 1    | Not listed        | NSAIDs            |

### Antipsychotics Restructured

| Drug Name           | 2025 Tier | 2026 Tier                        | Notes                     |
| ------------------- | --------- | -------------------------------- | ------------------------- |
| **CAPLYTA**         | Tier 3    | Tier 4                           | Added PA, ST requirements |
| **lurasidone hcl**  | Tier 3    | Not listed separately            |                           |
| **paliperidone er** | Tier 3    | Not listed separately            |                           |
| **VRAYLAR**         | Tier 4    | Tier 4 (also in antidepressants) | Dual listing              |

---

## 4. Restriction Changes

### New Prior Authorization Requirements

| Drug Name                               | 2025 Requirements | 2026 Requirements |
| --------------------------------------- | ----------------- | ----------------- |
| **primidone 125mg**                     | None              | PA                |
| **MYSOLINE**                            | None              | PA                |
| **lamotrigine oral tablet dispersible** | None              | PA                |
| **CAPLYTA**                             | None              | PA, ST, QL        |
| **RALDESY**                             | None              | PA                |

### New Quantity Limits Added

| Drug Name                                   | 2025 | 2026 |
| ------------------------------------------- | ---- | ---- |
| **acetaminophen-codeine oral tablet**       | None | QL   |
| **ascomp-codeine**                          | None | QL   |
| **butalbital-apap-caffeine**                | None | QL   |
| **morphine sulfate oral tablet**            | None | QL   |
| **oxycodone hcl (all forms)**               | None | QL   |
| **oxycodone-acetaminophen (all strengths)** | None | QL   |
| **tramadol hcl 50mg**                       | None | QL   |
| **tramadol-acetaminophen**                  | None | QL   |
| **hydromorphone hcl oral tablet**           | None | QL   |
| **naltrexone hcl oral**                     | None | QL   |
| **lidocaine external ointment 5%**          | None | QL   |

### New Step Therapy Requirements

| Drug Name         | 2025 | 2026                     |
| ----------------- | ---- | ------------------------ |
| **CAPLYTA**       | None | ST                       |
| **nilotinib hcl** | None | ST (added to PA, QL, SP) |

### Removed Restrictions

| Drug Name                | 2025 Requirements | 2026 Requirements  |
| ------------------------ | ----------------- | ------------------ |
| **clobazam oral tablet** | PA                | PA (unchanged)     |
| **EPIDIOLEX**            | PA, SP            | PA, SP (unchanged) |

---

## 5. Biosimilar and Generic Conversions

### New Generics Available in 2026

| Brand Name  | Generic Name            | 2026 Tier | Significance                                   |
| ----------- | ----------------------- | --------- | ---------------------------------------------- |
| **XARELTO** | rivaroxaban             | Tier 2    | Major anticoagulant - significant cost savings |
| **TASIGNA** | nilotinib hcl           | Tier 2    | CML treatment                                  |
| **APTIOM**  | eslicarbazepine acetate | Tier 3    | Seizure medication                             |
| **FYCOMPA** | perampanel              | Tier 2    | Seizure medication                             |
| **VIMPAT**  | lacosamide              | Tier 2    | Seizure medication                             |

### Brand Exclusions Due to Generic Availability

| Brand Excluded | Generic Preferred             | Tier   |
| -------------- | ----------------------------- | ------ |
| **PRADAXA**    | dabigatran etexilate mesylate | Tier 2 |
| **LOVENOX**    | enoxaparin sodium             | Tier 2 |
| **DIFLUCAN**   | fluconazole                   | Tier 1 |
| **VALTREX**    | valacyclovir                  | Tier 1 |

---

## 6. Therapeutic Class Coverage Shifts

### Anticonvulsants - Major Restructuring

**Key Changes:**
- Added oxcarbazepine to Tier 1 (previously not listed)
- Generic lacosamide moved from Tier 3 to Tier 2
- Generic perampanel added at Tier 2
- APTIOM moved from Tier 3 to Tier 4
- Multiple specialty seizure medications removed (felbamate, vigabatrin, rufinamide, FINTEPLA)

### Oncology - Significant Formulary Reduction

**Removed Agents (17+ drugs):**
- BTK inhibitors: BRUKINSA
- Kinase inhibitors: BOSULIF, ICLUSIG, INLYTA, LENVIMA, pazopanib
- Targeted therapies: GAVRETO, VITRAKVI, KOSELUGO, EXKIVITY
- PARP inhibitors: ZEJULA
- Combination regimens: TAFINLAR/MEKINIST

**Added Agents:**
- AUGTYRO, SCEMBLIX, RYDAPT
- Generic nilotinib

**Impact:** Narrower oncology formulary with focus on specific agents; may require more prior authorizations for non-formulary alternatives.

### Anti-Addiction/Substance Abuse - Expanded Naloxone Access

**2026 Additions:**
- KLOXXADO (high-dose naloxone nasal)
- OPVEE (nalmefene nasal)
- Multiple store-brand naloxone products

**Removal:**
- acamprosate calcium (alcohol dependence)

### Smoking Cessation - Tier Restructuring

| Product                   | 2025 Tier  | 2026 Tier |
| ------------------------- | ---------- | --------- |
| Generic nicotine products | Tier 1     | Tier 1    |
| NICORETTE MINI/LOZENGE    | Tier 2     | Tier 2    |
| NICODERM CQ               | Tier 1-2   | Tier 4    |
| NICORETTE GUM             | Tier 2     | Tier 4    |
| NICORETTE STARTER KIT     | Not listed | Tier 4    |
| THRIVE                    | Not listed | Tier 4    |

**Impact:** Brand-name smoking cessation products significantly more expensive; generics remain preferred.

### Anticoagulants - Generic Rivaroxaban Impact

**Major Change:** Generic rivaroxaban added at Tier 2
- XARELTO brand remains at Tier 2
- Starter packs removed from formulary
- fondaparinux removed

---

## 7. Summary Tables

### High-Impact Changes for Plan Sponsors

| Change Type                 | Count | Cost Impact   |
| --------------------------- | ----- | ------------- |
| New generics (cost savings) | 8+    | ↓ Significant |
| Brand exclusions            | 25+   | ↓ Moderate    |
| Tier increases              | 10+   | ↑ Moderate    |
| New specialty drugs         | 5+    | ↑ High        |
| Oncology removals           | 17+   | Variable      |
| New QL restrictions         | 15+   | ↓ Utilization |

### Member Impact Summary

| Therapeutic Area  | Impact Level     | Action Required                       |
| ----------------- | ---------------- | ------------------------------------- |
| Oncology          | **HIGH**         | Review alternative coverage options   |
| Anticonvulsants   | **MODERATE**     | Some medications removed/restructured |
| Opioid Analgesics | **MODERATE**     | New quantity limits on most products  |
| Smoking Cessation | **LOW-MODERATE** | Brand products more expensive         |
| Anticoagulants    | **POSITIVE**     | Generic rivaroxaban = cost savings    |
| Antidementia      | **POSITIVE**     | Rivastigmine moved to Tier 1          |

---

## 8. Recommendations

### For Plan Sponsors:
1. **Oncology Review:** Evaluate medical benefit coverage for removed oral oncology agents
2. **Transition Planning:** Identify members on removed medications for proactive outreach
3. **Generic Substitution:** Promote rivaroxaban generic for cost savings
4. **Opioid Management:** Communicate new quantity limits to prescribers

### For Members:
1. **Check Coverage:** Verify current medications remain covered
2. **Generic Options:** Consider generic alternatives where available
3. **Prior Authorization:** Allow extra time for PA requirements on specialty medications
4. **Smoking Cessation:** Use generic nicotine products for lowest cost